AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26062731 — intervention group
Group type: EXPERIMENTAL
Intervention: G-I (one session treatment)
Number of subjects: 90
Study 26062731 — intervention group
Group type: EXPERIMENTAL
Intervention: G-II (two sessions treatment)
Number of subjects: 90
Study 26062731 — intervention group
Group type: EXPERIMENTAL
Intervention: G-I and G-II (both groups)
Number of subjects: 90
Study 26062731 — intervention group
Group type: COMPARATOR
Intervention: G-III (control group receiving regular liver treatment)
Number of subjects: 90
Study 23184569 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, 50 mg once daily
Number of subjects: 180
Study 23184569 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride, 10 mg once daily
Number of subjects: 180
Study 23184569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 21885980 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind Intubation Device (BID)
Number of subjects: 50
Study 21885980 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 50
Study 19489848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (given first)
Number of subjects: 48
Study 19489848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (given after methacholine)
Number of subjects: 48
Study 19489848 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (given first)
Number of subjects: 48
Study 19489848 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (given after mannitol)
Number of subjects: 48
Study 16769348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral recombinant human G‐CSF (rhG‐CSF) for 5 days
Number of subjects: 18
Study 16769348 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 18
Study 15293593 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol inhalation solution (Xopenex)
Number of subjects: 0
Study 15293593 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (R,S-albuterol)
Number of subjects: 0
Study 11813931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg BID (IR tablets)
Number of subjects: 160
Study 11813931 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 1 g OD (two 500-mg MR tablets)
Number of subjects: 160
Study 9742534 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective warming blankets (Group 2)
Number of subjects: 50
Study 9742534 — intervention group
Group type: COMPARATOR
Intervention: Heating mattress (Group 1)
Number of subjects: 50
Study 7527112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (total dose 4.2 x 10(6) kallikrein inhibiting units)
Number of subjects: 43
Study 7527112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (total dose 20 mg/kg body weight)
Number of subjects: 43
Study 7527112 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated controls
Number of subjects: 43
Study 7527112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin and Tranexamic acid
Number of subjects: 43
Study 7527112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 43
Study 3056473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training
Number of subjects: 52
Study 3056473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (colposuspension)
Number of subjects: 52
Study 3056473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (vaginal repair)
Number of subjects: 52
Study 3056473 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment radiologic reevaluation
Number of subjects: 52
Study 14530867 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA + MTX
Number of subjects: 105
Study 14530867 — intervention group
Group type: COMPARATOR
Intervention: CSA alone
Number of subjects: 105
Study 14530867 — intervention group
Group type: COMPARATOR
Intervention: CSA + HCQ
Number of subjects: 105
Study 31749301 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate intensity exercise during pregnancy
Number of subjects: 855
Study 31749301 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care during pregnancy
Number of subjects: 855
Study 30819259 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning-based treadmill training
Number of subjects: 18
Study 30819259 — intervention group
Group type: COMPARATOR
Intervention: Regular treadmill training
Number of subjects: 18
Study 28154462 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (1000 mg orally every 12 h for 5 consecutive treatments)
Number of subjects: 8
Study 28154462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 26925895 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (60-minute in-person training, 5 sessions over 8 weeks)
Number of subjects: 50
Study 26925895 — intervention group
Group type: COMPARATOR
Intervention: Routine training given to all patients in hemodialysis department (Control)
Number of subjects: 50
Study 24158787 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day) plus exemestane (25 mg/day)
Number of subjects: 0
Study 24158787 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane (25 mg/day)
Number of subjects: 0
Study 20379145 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese CP patients
Number of subjects: 54
Study 20379145 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight CP patients
Number of subjects: 54
Study 20379145 — intervention group
Group type: EXPERIMENTAL
Intervention: All CP patients
Number of subjects: 54
Study 20379145 — intervention group
Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 54
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Sup)
Number of subjects: 11
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position (Sit)
Number of subjects: 11
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine with legs up position (SupLu)
Number of subjects: 11
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position (Up)
Number of subjects: 11
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise condition (post-SI)
Number of subjects: 11
Study 19395660 — intervention group
Group type: EXPERIMENTAL
Intervention: All positions in N condition
Number of subjects: 11
Study 16546538 — intervention group
Group type: EXPERIMENTAL
Intervention: Community DOTS
Number of subjects: 907
Study 16546538 — intervention group
Group type: COMPARATOR
Intervention: Family-member DOTS
Number of subjects: 907
Study 15482516 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 67
Study 15482516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard differential pressure valve
Number of subjects: 344
Study 11155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta valve (PS Medical‐Medtronic)
Number of subjects: 344
Study 11155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigma valve (NMT Cordis)
Number of subjects: 344
Study 11155058 — intervention group
Group type: COMPARATOR
Intervention: Control group (differential pressure valves)
Number of subjects: 344
Study 9340608 — intervention group
Group type: EXPERIMENTAL
Intervention: Double phototherapy with Wallaby optic fibers
Number of subjects: 2
Study 9340608 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 2
Study 8034239 — intervention group
Group type: EXPERIMENTAL
Intervention: PC stored at 22 degrees C and incubated at 37 degrees C for 1 h before transfusion
Number of subjects: 22
Study 8034239 — intervention group
Group type: COMPARATOR
Intervention: Non-warmed PC
Number of subjects: 22
Study 8034239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pre-warmed and non-warmed PC
Number of subjects: 22
Study 2950464 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 73
Study 2950464 — intervention group
Group type: COMPARATOR
Intervention: Myelosuppression
Number of subjects: 73
Study 29789220 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 0
Study 29789220 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 0
Study 28236016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-covered stent
Number of subjects: 95
Study 28236016 — intervention group
Group type: COMPARATOR
Intervention: Semi-covered stent
Number of subjects: 95
Study 26710696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor augmented insulin pump (SAP)
Number of subjects: 81
Study 26710696 — intervention group
Group type: COMPARATOR
Intervention: Double C therapy (continuous subcutaneous insulin infusion and retrospective continuous glucose monitoring)
Number of subjects: 81
Study 23433188 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-APC infusion (24 mcg kg(‐1) h(‐1) for 96 h)
Number of subjects: 27
Study 23433188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21674864 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy (RT)
Number of subjects: 40
Study 21674864 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 40
Study 18783459 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 7354
Study 18783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider Counseling
Number of subjects: 7354
Study 18783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider Counseling + Pharmacotherapy
Number of subjects: 7354
Study 18783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline with nicotine patch
Number of subjects: 7354
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET and CT imaging in patients with organising pneumonia
Number of subjects: 88
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET and CT imaging in patients with air-space consolidation
Number of subjects: 88
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD45(+) cells with maximal SUV
Number of subjects: 88
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD8(+) T lymphocytes with maximal SUV
Number of subjects: 88
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD45(+) cells with maximal LNR
Number of subjects: 88
Study 16568202 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD8(+) T lymphocytes with maximal LNR
Number of subjects: 88
Study 12907900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein-bound polysaccharide K plus 300 mg tegafur/uracil
Number of subjects: 201
Study 12907900 — intervention group
Group type: COMPARATOR
Intervention: 300 mg tegafur/uracil alone
Number of subjects: 201
Study 10539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 10 mg
Number of subjects: 82
Study 10539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg
Number of subjects: 82
Study 10539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 82
Study 10539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 82
Study 10539814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 10539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (all doses)
Number of subjects: 82
Study 8557919 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast
Number of subjects: 27
Study 8557919 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast (large-breasted group)
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast (large-breasted group)
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast (large-breasted group)
Number of subjects: 27
Study 8557919 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex defibrillation electrode on the breast (small-breasted group)
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode under the breast (small-breasted group)
Number of subjects: 27
Study 8557919 — intervention group
Group type: COMPARATOR
Intervention: Apex defibrillation electrode lateral to the breast (small-breasted group)
Number of subjects: 27
Study 1752890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 35
Study 1752890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6282105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils breakfast
Number of subjects: 7
Study 6282105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils breakfast followed by standard bread lunch
Number of subjects: 7
Study 6282105 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow feeding of bread breakfast over 4 hours
Number of subjects: 7
Study 6282105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread breakfast with a quarter of carbohydrate
Number of subjects: 7
Study 31397288 — intervention group
Group type: EXPERIMENTAL
Intervention: CSLT (computerised speech and language therapy) plus usual care
Number of subjects: 278
Study 31397288 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278
Study 31397288 — intervention group
Group type: COMPARATOR
Intervention: Attention control plus usual care
Number of subjects: 278
Study 31397288 — intervention group
Group type: EXPERIMENTAL
Intervention: CSLT (computerised speech and language therapy)
Number of subjects: 278
Study 31397288 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 278
Study 30221912 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-omega group (Symbiter Omega)
Number of subjects: 48
Study 30221912 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 48
Study 27030846 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with knee OA
Number of subjects: 11
Study 27030846 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 25248418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhoidal dearterialization with mucopexy
Number of subjects: 40
Study 25248418 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhoidectomy
Number of subjects: 40
Study 22134175 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone with drug abuse counseling
Number of subjects: 230
Study 22134175 — intervention group
Group type: COMPARATOR
Intervention: Methadone only
Number of subjects: 230
Study 19838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist empathic responses to patients' negative emotion
Number of subjects: 264
Study 19838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low economic security
Number of subjects: 264
Study 19838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 264
Study 19838742 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who knew their oncologist for more than a year
Number of subjects: 264
Study 19034342 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Mitomycin C instillation
Number of subjects: 63
Study 19034342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 63
Study 10930147 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic-guided therapy (G4)
Number of subjects: 81
Study 10930147 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 81
Study 10930147 — intervention group
Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 81
Study 10930147 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic-guided therapy (G3)
Number of subjects: 81
Study 9513828 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal hypertensive gastropathy in patients with cirrhosis
Number of subjects: 0
Study 9513828 — intervention group
Group type: COMPARATOR
Intervention: Portal hypertensive gastropathy in controls without cirrhosis
Number of subjects: 0
Study 9513828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic-like pattern
Number of subjects: 0
Study 9513828 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity of portal hypertensive gastropathy
Number of subjects: 0
Study 9513828 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of portal hypertensive gastropathy
Number of subjects: 0
Study 8452173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 191
Study 8452173 — intervention group
Group type: COMPARATOR
Intervention: AMX/CP 500 mg/125 mg three times a day
Number of subjects: 191
Study 3785797 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil cream (5%, applied biweekly for at least six months)
Number of subjects: 90
Study 3785797 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic 5-fluorouracil cream
Number of subjects: 90
Study 28984095 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia and continuous wound infusion of anesthetics
Number of subjects: 96
Study 28984095 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia and continuous wound infusion of saline solution
Number of subjects: 96
Study 27601354 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group using mobile app
Number of subjects: 139
Study 27601354 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised group using mobile app
Number of subjects: 139
Study 27601354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 139
Study 27601354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both app-using groups
Number of subjects: 139
Study 25091593 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy (CBT) - eight sessions led by trained psychologists on a weekly basis
Number of subjects: 216
Study 25091593 — intervention group
Group type: COMPARATOR
Intervention: Usual care from primary care centers
Number of subjects: 216
Study 24370796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical heart valve prosthesis
Number of subjects: 223
Study 24370796 — intervention group
Group type: COMPARATOR
Intervention: Biological heart valve prosthesis
Number of subjects: 223
Study 20012343 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted occupational health intervention
Number of subjects: 382
Study 20012343 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study 19441667 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (n=51) with a dose range of 10-20 mg/day
Number of subjects: 90
Study 19441667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (n=39) with a dose range of 75-150 mg/day
Number of subjects: 90
Study 16820255 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (initial dose of at least 10 mg/day, mean dose 12.2 mg/day, S.D. = 5.8)
Number of subjects: 235
Study 16820255 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (initial dose of at least 3 mg/day, mean dose 4.9 mg/day, S.D. = 2)
Number of subjects: 235
Study 12771003 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal BNP (N-BNP)
Number of subjects: 666
Study 12771003 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 666
Study 12771003 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF <40% coupled to N-BNP over the group median
Number of subjects: 666
Study 12771003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of N-BNP (or BNP) with LVEF
Number of subjects: 666
Study 12771003 — intervention group
Group type: EXPERIMENTAL
Intervention: N-BNP and BNP
Number of subjects: 666
Study 10759936 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS (percutaneous electrical nerve stimulation)
Number of subjects: 30
Study 10759936 — intervention group
Group type: COMPARATOR
Intervention: Needles alone
Number of subjects: 30
Study 8682264 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological examination using CBA-H questionnaire
Number of subjects: 2705
Study 1506124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gincosan (60 mg ginkgo biloba + 100 mg ginseng)
Number of subjects: 10
Study 1506124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gincosan (120 mg ginkgo biloba + 200 mg ginseng)
Number of subjects: 10
Study 1506124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30806538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichiasis in adults aged ≥15 years
Number of subjects: 56349
Study 30806538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachomatous inflammation—follicular (TF) in children aged 1–9 years
Number of subjects: 56349
Study 30806538 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence of trichiasis
Number of subjects: 56349
Study 26985728 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions (1 in person and 2 by phone)
Number of subjects: 307
Study 26985728 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 307
Study 26985728 — intervention group
Group type: COMPARATOR
Intervention: Control - printed literature about alcohol and drug use risks
Number of subjects: 307
Study 25015547 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie labeling implementation in Philadelphia
Number of subjects: 0
Study 22991113 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention (7-8 sessions after work period)
Number of subjects: 18
Study 20435968 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 219
Study 20435968 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (local traditional vocational services)
Number of subjects: 219
Study 18386573 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint group (needling at Zusanli ST36)
Number of subjects: 26